Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 52
- Registration Number
- NCT01473563
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 195
- Registration Number
- NCT01469000
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 472
- Registration Number
- NCT01454102
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦Local Institution, Toronto, Ontario, Canada
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01447225
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT01445392
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
- Conditions
- Interventions
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT01443078
- Locations
- 🇺🇸
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 24
- Registration Number
- NCT01397305
- Locations
- 🇸🇪
Sahlgrenska University Hospital, Göteborg, Sweden
Cisplatin and Pemetrexed With Radiation Followed by Lobectomy
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 48
- Registration Number
- NCT01373463
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
- Conditions
- Interventions
- First Posted Date
- 2011-05-24
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01358968
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2011-05-13
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- University College, London
- Registration Number
- NCT01353482
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.